Title: Fenofibrate: An Underused Drug in Treatment of ARDS in COVID-19
Authors: Dr Sidhartha Sankar Bhuyan, Dr Rakesh Mohanty, Dr Swayamprava Sasmal
DOI: https://dx.doi.org/10.18535/jmscr/v8i10.38
Abstract
Most of the deaths caused by the severe acute respiratory syndrome corona virus 2 (sars-cov-2) is attributable to the high incidence of Acute respiratory distress syndrome (ARDS).The mechanism of ARDS has been debatable, with recent researches postulating an inflammatory induced pro-thrombotic state associated with abnormal lipid generation. Fenofibrate, a widely available low-cost generic drug approved by the FDA, may be beneficial in covid-19 owing to its lipid lowering as well as immunomodulatory effects.
Keywords: Covid-19 , ARDS, Fenofibrate.
References
- Ranieri VM Rubenfeld GD Thompson BT et al. Acute respiratory distress syndrome: the Berlin Definition. 2012; 307: 2526-2533
- Sebag SC Bastarache JA Ware LB Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome. Curr Pharm Biotechnol. 2011; 12: 1481-1496
- Mehta P, McAuley DF, Brown M, et al. COVID-19: con- sider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–. Epub 2020 Mar 16.
- Ji HL Zhao R Matalon S Matthay MA, Elevated plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility. Physiol Rev. 2020; 100: 1065-1075
- Prabhakaran P Ware LB White KE Cross MT Matthay MA Olman MA, Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2003; 285: L20-L28
- Greene R Zapol WM Snider MT et al. Early bedside detection of pulmonary vascular occlusion during acute respiratory failure. Am Rev Respir Dis. 1981; 124: 593-601
- Dolhnikoff M Duarte-Neto AN de Almeida Monteiro RA et al.Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19.J Thromb Haemost. 2020; 18: 1517-1519
- Ackermann M Verleden SE Kuehnel M et al.Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19.N Engl J Med. 2020; 383: 120-128
- nchi.nlm.nih.gov
- Prasad GS, Govardhan P, Deepika G, et al. Anti- inflammatory activity of anti-hyperlipidemic drug, fenofibrate, and its phase-I metabolite fenofibric acid: in silico, in vitro, and in vivo studies. 2018;26(4):973–981.
- Chan NN, Chow FC. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet. 2001;358(9295):1811.
- Ibarra-Lara L, Hong E, Soria-Castro E, et al. Clofibrate PPARα activation reduces oxidative stress and improves ultrastructure and ventricular hemody- namics in no-flow myocardial ischemia. J Cardiovasc. 2012;60(4):323–334.
- Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS corona- virus infection and spread. Virol J. 2005 Aug 22;2: 69.
- Pastick KA, Okafor EC, Lofgren SM, et al. Review:hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis. 2020;7(4):ofaa130.